Edgewise Therapeutics Inc (EWTX) concluded trading on Wednesday at a closing price of $14.47, with 0.44 million shares of worth about $6.32 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.61% during that period and on June 18, 2025 the price saw a loss of about -0.14%. Currently the company’s common shares owned by public are about 95.21M shares, out of which, 77.10M shares are available for trading.
Stock saw a price change of -8.13% in past 5 days and over the past one month there was a price change of -2.16%. Year-to-date (YTD), EWTX shares are showing a performance of -45.81% which decreased to -17.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.60 but also hit the highest price of $38.12 during that period. The average intraday trading volume for Edgewise Therapeutics Inc shares is 1.68 million. The stock is currently trading -1.86% below its 20-day simple moving average (SMA20), while that difference is down -0.15% for SMA50 and it goes to -40.40% lower than SMA200.
Edgewise Therapeutics Inc (NASDAQ: EWTX) currently have 95.21M outstanding shares and institutions hold larger chunk of about 74.67% of that.
The stock has a current market capitalization of $1.52B and its 3Y-monthly beta is at 0.29. It has posted earnings per share of -$1.55 in the same period. It has Quick Ratio of 20.99 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EWTX, volatility over the week remained 1.72% while standing at 2.34% over the month.
Analysts are in expectations that Edgewise Therapeutics Inc (EWTX) stock would likely to be making an EPS of -0.42 in the current quarter, while forecast for next quarter EPS is -0.44 and it is -1.97 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.48 which is -0.38 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.34 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -20.23% while it is estimated to decrease by -9.80% in next year. EPS is likely to grow at an annualized rate of -9.15% for next 5-years, compared to annual growth of -49.00% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Guggenheim on April 30, 2025 offering a Buy rating for the stock and assigned a target price of $41 to it. Coverage by Scotiabank stated Edgewise Therapeutics Inc (EWTX) stock as a Sector perform in their note to investors on April 02, 2025, suggesting a price target of $14 for the stock. On March 07, 2025, Scotiabank Initiated their recommendations, while on January 22, 2025, Stifel Initiated their ratings for the stock with a price target of $30. Stock get an Outperform rating from Evercore ISI on November 22, 2024.
